- Home
- TSSI vs PHAR Comparison
TSSI vs PHAR Comparison
Compare TSSI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSSI
- PHAR
- Stock Information
- Founded
- TSSI 2004
- PHAR 1988
- Country
- TSSI United States
- PHAR Netherlands
- Employees
- TSSI N/A
- PHAR N/A
- Industry
- TSSI Professional Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- TSSI Consumer Discretionary
- PHAR Health Care
- Exchange
- TSSI Nasdaq
- PHAR Nasdaq
- Market Cap
- TSSI 640.8M
- PHAR 731.1M
- IPO Year
- TSSI N/A
- PHAR N/A
- Fundamental
- Price
- TSSI $20.68
- PHAR $10.00
- Analyst Decision
- TSSI
- PHAR Strong Buy
- Analyst Count
- TSSI 0
- PHAR 3
- Target Price
- TSSI N/A
- PHAR $30.00
- AVG Volume (30 Days)
- TSSI 2.8M
- PHAR 3.6K
- Earning Date
- TSSI 08-21-2025
- PHAR 07-31-2025
- Dividend Yield
- TSSI N/A
- PHAR N/A
- EPS Growth
- TSSI 770.13
- PHAR N/A
- EPS
- TSSI 0.35
- PHAR N/A
- Revenue
- TSSI $231,211,000.00
- PHAR $320,708,000.00
- Revenue This Year
- TSSI N/A
- PHAR $13.31
- Revenue Next Year
- TSSI N/A
- PHAR $7.68
- P/E Ratio
- TSSI $65.30
- PHAR N/A
- Revenue Growth
- TSSI 262.87
- PHAR 24.13
- 52 Week Low
- TSSI $2.12
- PHAR $6.65
- 52 Week High
- TSSI $31.94
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- TSSI N/A
- PHAR 43.61
- Support Level
- TSSI N/A
- PHAR $9.99
- Resistance Level
- TSSI N/A
- PHAR $10.59
- Average True Range (ATR)
- TSSI 0.00
- PHAR 0.35
- MACD
- TSSI 0.00
- PHAR -0.14
- Stochastic Oscillator
- TSSI 0.00
- PHAR 7.45
About TSSI TSS Inc. Common Stock
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.